doi: 10.3389/fphar.2025.1601712 Received 28 March 2025 Accepted 27 May 2025 Published 23 June 2025 Volume 16 - 2025 Edited by Ashish Mehta, Garvan Institute of Medical Research, Australia Reviewed by Ankul Singh S, ACS Medical College and Hospital, India Prabhash Nath Tripathi, University of Arkansas for Medical Sciences, United States Updates Copyright 2025 Aktary, Jeong, Oh, Shin, Sung, Rahman, Ramos Santiago, Choi, Song, Nurkolis, Ribeiro, Park and Kim
We solicited comments on the potential benefits and drawbacks of using a Beneficiary-Pharmacy Methodology and on whether a Beneficiary-Pharmacy Methodology could be combined with the Prescriber-Pharmacy Methodology to validate 340B units identified, such as via a union of the two methodologies
At Biomed Mobile IV & Wellness, we bring professional peptide therapy directly to you throughout Colorado's Front Range
It didn't feature heavily in medical school curricula